| Spatial orientation (MMSE), points | Healthy older people; analysis 28/33. MMSE Spatial orientation (score): At baseline 4.4 ± 0.7 versus 4.0 ± 0.8; change over 24 weeks 0.4 ± 0.9 versus 0.6 ± 0.9, p=0.446; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 4.4 ± 0.7 versus 4.0 ± 0.8; change over 24 weeks 0.4 ± 0.9 versus 0.6 ± 0.9, p=0.446; mean ± SD. | 2/4 LowLow confidence in the difference in changes in MMSE Spatial orientation (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Registration (MMSE), points | Healthy older people; analysis 28/33. MMSE Registration (score): At baseline 2.9 ± 0.6 versus 3.0 ± 0.0; change over 24 weeks 0.1 ± 0.6 versus 0.0 ± 0.0, p=0.212; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 2.9 ± 0.6 versus 3.0 ± 0.0; change over 24 weeks 0.1 ± 0.6 versus 0.0 ± 0.0, p=0.212; mean ± SD. | 2/4 LowLow confidence in the difference in changes in MMSE Registration (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Attention (MMSE), points | Healthy older people; analysis 28/33. MMSE Attention (score): At baseline 4.0 ± 0.9 versus 4.2 ± 1.0; change over 24 weeks 0.6 ± 1.2 versus 0.3 ± 1.0, p=0.286; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 4.0 ± 0.9 versus 4.2 ± 1.0; change over 24 weeks 0.6 ± 1.2 versus 0.3 ± 1.0, p=0.286; mean ± SD. | 2/4 LowLow confidence in the difference in changes in MMSE Attention (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Recall from memory (MMSE), points | Healthy older people; analysis 28/33. MMSE Remote memory (score): At baseline 2.7 ± 0.5 versus 2.8 ± 0.5; change over 24 weeks 0.3 ± 0.6 versus 0.1 ± 0.6, p=0.292; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 2.7 ± 0.5 versus 2.8 ± 0.5; change over 24 weeks 0.3 ± 0.6 versus 0.1 ± 0.6, p=0.292; mean ± SD. | 2/4 LowLow confidence in the difference in changes in MMSE Remote memory (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Naming two objects (MMSE), points | Healthy older people; analysis 28/33. MMSE Naming two objects (score): At baseline 2.0 ± 0.0 versus 2.0 ± 0.0; change over 24 weeks 0.0 ± 0.0 versus 0.0 ± 0.0, p=1.000; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 2.0 ± 0.0 versus 2.0 ± 0.0; change over 24 weeks 0.0 ± 0.0 versus 0.0 ± 0.0, p=1.000; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Naming two objects (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Naming: both groups had baseline 2.0±0.0 and Δ0.0±0.0; all observed values were at the ceiling, and p=1 does not prove equivalence in the population. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Repeating a phrase (MMSE), points | Healthy older people; analysis 28/33. MMSE Repeat (score): At baseline 0.8 ± 0.4 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.4 versus −0.1 ± 0.2, p=0.275; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 0.8 ± 0.4 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.4 versus −0.1 ± 0.2, p=0.275; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Repeat (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Repeat: the baseline difference 0.8±0.4 versus 1.0±0.0, p=0.022, pertains to baseline; p=0.275 pertains to change at week 24. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Following an instruction (MMSE), points | Healthy older people; analysis 28/33. MMSE Stage command (score): At baseline 2.8 ± 0.4 versus 2.6 ± 0.6; change over 24 weeks 0.1 ± 0.6 versus 0.2 ± 0.7, p=0.821; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 2.8 ± 0.4 versus 2.6 ± 0.6; change over 24 weeks 0.1 ± 0.6 versus 0.2 ± 0.7, p=0.821; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Stage command (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Stage command: baseline scores 2.8 and 2.6 were close to the upper limit, limiting room for improvement; observed changes were 0.1 versus 0.2. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Writing a sentence (MMSE), points | Healthy older people; analysis 28/33. MMSE Writing a complete sentence (score): At baseline 1.0 ± 0.2 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.3 versus 0.0 ± 0.2, p=0.601; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 1.0 ± 0.2 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.3 versus 0.0 ± 0.2, p=0.601; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Writing a complete sentence (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Sentence writing: rounded baseline values of 1.0 in both groups indicate a ceiling limitation; nonzero SDs are retained as published. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Reading and following an instruction (MMSE), points | Healthy older people; analysis 28/33. MMSE Reading and obey (score): At baseline 0.9 ± 0.4 versus 0.9 ± 0.3; change over 24 weeks −0.1 ± 0.4 versus −0.1 ± 0.3, p=0.859; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 0.9 ± 0.4 versus 0.9 ± 0.3; change over 24 weeks −0.1 ± 0.4 versus −0.1 ± 0.3, p=0.859; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Reading and obey (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Reading and obeying: baseline values 0.9 and changes −0.1 in both groups, but the available variability does not establish equivalence. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Copying a drawing (MMSE), points | Healthy older people; analysis 28/33. MMSE Copy the diagram (score): At baseline 0.9 ± 0.4 versus 1.0 ± 0.2; change over 24 weeks 0.1 ± 0.4 versus −0.1 ± 0.2, p=0.067; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 0.9 ± 0.4 versus 1.0 ± 0.2; change over 24 weeks 0.1 ± 0.4 versus −0.1 ± 0.2, p=0.067; mean ± SD. | 2/4 LowLow confidence in the comparison of changes in MMSE Copy the diagram (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Copying: for Δ12 weeks p=0.024, for Δ24 weeks p=0.067; these are different comparisons and the first cannot be transferred to the second. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| CADi2 total score, points | Healthy older people; analysis 28/33. CADi2 total score (score): At baseline 9.3 ± 1.0 versus 8.8 ± 1.0; change over 24 weeks 0.0 ± 0.9 versus 0.2 ± 1.0, p=0.262; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 9.3 ± 1.0 versus 8.8 ± 1.0; change over 24 weeks 0.0 ± 0.9 versus 0.2 ± 1.0, p=0.262; mean ± SD. | 2/4 LowLow confidence in the comparison of CADi2 total score (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The active group had 9.3 versus 8.8 at baseline (p=0.014); this is a baseline difference, not a treatment effect. For Δ24 p=0.262. The data do not isolate the effect of quercetin alone. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| CADi2 completion time, seconds | Healthy older people; analysis 28/33. CADi2 total response time (s): At baseline 98.9 ± 34.8 versus 94.5 ± 22.1; change over 24 weeks −11.9 ± 33.4 versus −7.3 ± 21.5, p=0.728; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 98.9 ± 34.8 versus 94.5 ± 22.1; change over 24 weeks −11.9 ± 33.4 versus −7.3 ± 21.5, p=0.728; mean ± SD. | 2/4 LowLow confidence in the comparison of CADi2 total response time (s) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. Response time Δ12 has p=0.047 and Δ24 p=0.728; these time points and comparisons must not be conflated. Negative changes indicate shorter time, not improvement in all cognitive functions. The data do not isolate the effect of quercetin alone. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Low mood (Self-rating Depression Scale, SDS), points | Healthy older people; analysis 28/33. Self-rating Depression Scale (score): At baseline 32.5 ± 7.7 versus 33.1 ± 5.9; change over 24 weeks −2.4 ± 5.0 versus −0.1 ± 4.9, p=0.020*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 32.5 ± 7.7 versus 33.1 ± 5.9; change over 24 weeks −2.4 ± 5.0 versus −0.1 ± 4.9, p=0.020*; mean ± SD. | 2/4 LowLow confidence in the comparison of Self-rating Depression Scale (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The difference in SDS changes at 24 weeks has p=0.020; this is a separate mood scale in healthy older adults, not a diagnosis or proven treatment of depression. The data do not isolate the effect of quercetin alone. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Apathy — indifference (Apathy Scale), points | Healthy older people; analysis 28/33. Apathy Scale (score): At baseline 6.4 ± 4.8 versus 4.8 ± 4.1; change over 24 weeks −2.6 ± 3.8 versus −0.1 ± 3.0, p=0.021*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 6.4 ± 4.8 versus 4.8 ± 4.1; change over 24 weeks −2.6 ± 3.8 versus −0.1 ± 3.0, p=0.021*; mean ± SD. | 2/4 LowLow confidence in the comparison of Apathy Scale (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The difference in Apathy Scale changes at 24 weeks has p=0.021; baseline 6.4 versus 4.8 and the possible influence of baseline differences remain important. This is a separate scale, not evidence of an effect on all cognition. The data do not isolate the effect of quercetin alone. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| Word recall (separate test), points | Healthy older people; analysis 28/33. Verbal recall test (score): At baseline 9.6 ± 2.5 versus 10.2 ± 1.8; change over 24 weeks 1.8 ± 3.1 versus 1.2 ± 2.2, p=0.640; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 9.6 ± 2.5 versus 10.2 ± 1.8; change over 24 weeks 1.8 ± 3.1 versus 1.2 ± 2.2, p=0.640; mean ± SD. | 2/4 LowLow confidence in the comparison of Verbal recall test (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. For verbal recall, group changes were 1.8 and 1.2, p=0.640; lack of significance establishes neither absence of effect nor equivalence. The data do not isolate the effect of quercetin alone. | 1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗ | Healthy older people; analysis 28/33 | - The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
|
|---|
| muscle soreness 0–24 hours after exercise | A review of four assessments of post-exercise soreness found a reduction on average: SMD −1.33 (95% CI −2.57…−0.09), p=0.03, I²=87%. Heterogeneity was high, and participant independence was not confirmed.SMD −1.33 (95% CI −2.57…−0.09), p=0.03, I²=87%. | 1/4 Very lowVery low confidence in the pooled muscle soreness effect: serious heterogeneity, wide uncertainty in the effect and methodological limitations of included trials. The number 68 is the sum of publication Ns, not confirmed unique participants; review time points are described inconsistently. | 11 review; 4 assessments from 4 publications; 68 participants in total according to the publications, participant independence was not establishedQuercetin supplementation promotes recovery after exercise-induced muscle damage: a systematic review and meta-analysis of randomized controlled trials ↗ | Young participants after intense exercise; a total of 68 participants across four publications, possible overlap was not checked | - Quercetin supplementation promotes recovery after exercise-induced muscle damage: a systematic review and meta-analysis of randomized controlled trials ↗
|
|---|
| days with symptoms | Community adults; 1002 study completers, symptom analysis 315/315/317. days with symptoms: 8.5±0.5 and 8.5±0.5 versus 8.4±0.5 days, p=0.982; mean ± SEM. The result applies to the combination, not to quercetin alone.8.5±0.5 and 8.5±0.5 versus 8.4±0.5 days, p=0.982; mean ± SEM. | 3/4 ModerateModerate confidence: the numbers of days with symptoms were similar between groups, but comparison precision leaves uncertainty about a small change in sick days. Questionnaire analysis covered 947 participants; 1002 completed the study. The conclusion concerns the combination, not quercetin alone. | 11 studyQuercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗ | Community adults; 1002 study completers, symptom analysis 315/315/317 | - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
|
|---|
| symptom severity | Community adults; 1002 study completers, symptom analysis 315/315/317. symptom severity: 18.3±1.2 and 19.8±1.3 versus 19.3±1.3 points, p=0.670; mean ± SEM. The result applies to the combination, not to quercetin alone.18.3±1.2 and 19.8±1.3 versus 19.3±1.3 points, p=0.670; mean ± SEM. | 3/4 ModerateModerate confidence: no clear difference in total severity over 12 weeks was established. The data still allow differences in cumulative symptom burden. This is an analysis of questionnaires from 947 participants for the combination of quercetin, vitamin C and niacin. | 11 studyQuercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗ | Community adults; 1002 study completers, symptom analysis 315/315/317 | - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
|
|---|
| total symptom score | Community adults; 1002 study completers, symptom analysis 315/315/317. total symptom score: 108±8.3 and 111±8.0 versus 108±8.0 points, p=0.946; mean ± SEM. The result applies to the combination, not to quercetin alone.108±8.3 and 111±8.0 versus 108±8.0 points, p=0.946; mean ± SEM. | 3/4 ModerateModerate confidence: total symptom scores were similar, but precision of the questionnaire analysis of 947 participants leaves uncertainty about the magnitude of a possible change. Statistical non-significance does not prove equality. The conclusion concerns the combination. | 11 studyQuercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗ | Community adults; 1002 study completers, symptom analysis 315/315/317 | - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
|
|---|
| JRQLQ total score | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ total score: At the end 19.1±12.1 versus 26.3±15.0, p=0.04; change −15.6±17.5 versus −8.4±18.5, p=0.13. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.At the end 19.1±12.1 versus 26.3±15.0, p=0.04; change −15.6±17.5 versus −8.4±18.5, p=0.13. Mean ± SD. | 2/4 LowLow confidence in the comparison of JRQLQ total score for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Final total score p=0.04, but change from baseline p=0.13; these comparisons are not equivalent. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| combined nose and eye symptoms | Adults in Japan with hay fever symptoms; analysis 30/30. combined nose and eye symptoms: Change −2.6±5.1 versus −1.6±5.3, p=0.44. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Change −2.6±5.1 versus −1.6±5.3, p=0.44. Mean ± SD. | 2/4 LowLow confidence in the comparison of total nasal and eye symptoms for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Change in the sum of nasal/eye symptoms p=0.44; lack of significance does not establish equivalence. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| JRQLQ quality of life | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ quality of life: At the end 11.6±9.1 versus 17.6±11.4, p=0.02; change −12.9±13.8 versus −6.8±14.1, p=0.10. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.At the end 11.6±9.1 versus 17.6±11.4, p=0.02; change −12.9±13.8 versus −6.8±14.1, p=0.10. Mean ± SD. | 2/4 LowLow confidence in the comparison of JRQLQ quality of life for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Final QOL p=0.02, but comparative change p=0.10; the final result does not replace a comparison of changes. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| JRQLQ sleep item | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sleep item: Change −1.0±0.9 versus −0.1±1.0; the source rounds p to 0.00. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Change −1.0±0.9 versus −0.1±1.0; the source rounds p to 0.00. Mean ± SD. | 2/4 LowLow confidence in the comparison of JRQLQ sleep item for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. The printed p=0.00 is a rounded value, not an exact zero. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| physical symptoms (JRQLQ domain) | Adults in Japan with hay fever symptoms; analysis 30/30. physical symptoms (JRQLQ domain): Change −2.1±1.8 versus −1.0±2.0, p=0.03. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Change −2.1±1.8 versus −1.0±2.0, p=0.03. Mean ± SD. | 2/4 LowLow confidence in the comparison of physical symptoms (JRQLQ domain) for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. The physical domain is part of one questionnaire, not a separate trial; p=0.03 for change. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| JRQLQ sneezing at week 4 | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sneezing at week 4: Median (Q1–Q3): 1.0 (1.0–2.0) versus 1.5 (1.0–2.0), p=0.04. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Median (Q1–Q3): 1.0 (1.0–2.0) versus 1.5 (1.0–2.0), p=0.04. | 2/4 LowLow confidence in the comparison of JRQLQ sneezing at week 4 for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Sneezing in Table III is a final median and interquartile range at week 4, not mean±SD or a change; the different rhinitis scale in Table IV has different baseline levels and does not substitute for JRQLQ here. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| JRQLQ nasal discharge at week 4 | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ nasal discharge at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.23. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.23. | 2/4 LowLow confidence in the comparison of JRQLQ nasal discharge at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. JRQLQ nasal discharge: medians at week 4 are equal, but IQRs are not; p=0.23 does not establish equivalence. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| JRQLQ itchy eyes at week 4 | Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ itchy eyes at week 4: Median (Q1–Q3): 1.5 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.55. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Median (Q1–Q3): 1.5 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.55. | 2/4 LowLow confidence in the comparison of JRQLQ eye itching at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. JRQLQ eye itching: week 4 p=0.55; this is a separate scale from the rhinitis scale and is not a comparison of change. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| sneezing on the rhinitis scale at week 4 | Adults in Japan with hay fever symptoms; analysis 30/30. sneezing on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.01. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement. | 2/4 LowLow confidence in the comparison of rhinitis-scale sneezing at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale sneezing: before intervention medians 1 versus 2 and p=0.04, and at week 4 p=0.01; without comparative analysis of change the final difference does not prove additional improvement. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| Runny nose on the rhinitis scale at week 4 | Adults in Japan with hay fever symptoms; analysis 30/30. rhinorrhea on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.5 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.5 (1.0–2.0), p=0.01. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement. | 2/4 LowLow confidence in the comparison of rhinitis-scale rhinorrhea at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale rhinorrhea: before intervention medians 1 versus 2 and p=0.04, and at week 4 p=0.01; additional improvement versus placebo is not established. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| itchy eyes on the rhinitis scale at week 1 | Adults in Japan with hay fever symptoms; analysis 30/30. itchy eyes on the rhinitis scale at week 1: Median (Q1–Q3): 1.0 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.02; at week 4 p=0.22. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.Median (Q1–Q3): 1.0 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.02; at week 4 p=0.22. | 2/4 LowLow confidence in the comparison of rhinitis-scale eye itching at week 1 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale eye itching: week 1 p=0.02, week 4 p=0.22; these are different time points and not JRQLQ. The week 1 effect should not be transferred to week 4. | 11 studyEffects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ | Adults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed. | - Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
|
|---|
| days ill in the exploratory subgroup | High self-rated physical fitness, age 40 years and older; 325 in total across all groups. days ill in the exploratory subgroup: 31% reduction in days with symptoms versus placebo, p=0.048. Exploratory subgroup of the same trial; group sizes were not reported.31% reduction in days with symptoms versus placebo, p=0.048. | 2/4 LowLow confidence in the comparison of the Q1000 combination with placebo in the selected subgroup: the reported result arose among many subgroups in the absence of an overall effect, and comparative uncertainty and the sizes of the two groups were not reported. An effect cannot be attributed to quercetin alone. | 11 studyQuercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗ | High self-rated physical fitness, age 40 years and older; 325 in total across all groups | - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
|
|---|
| severity in the exploratory subgroup | High self-rated physical fitness, age 40 years and older; 325 in total across all groups. severity in the exploratory subgroup: 36% reduction in severity versus placebo, p=0.020. Exploratory subgroup of the same trial; group sizes were not reported.36% reduction in severity versus placebo, p=0.020. | 2/4 LowLow confidence in the comparison of the Q1000 combination with placebo in the selected subgroup: the reported result arose among many subgroups in the absence of an overall effect, and comparative uncertainty and the sizes of the two groups were not reported. An effect cannot be attributed to quercetin alone. | 11 studyQuercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗ | High self-rated physical fitness, age 40 years and older; 325 in total across all groups | - Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
|
|---|